Millions of satisfied women1

Paragard® IUS scores high on patient satisfaction and continuation rates2,3

94%

of women using Paragard have reported satisfaction at 3 and 6 months postplacement.2

Continuation Rates

Paragard continuation rates are equal to or greater than those of other LARCs3*

Contraceptive continuation rates at 12 months among women ≥26 years of age (n=2,956)3†‡

Chart that shows continuation rates among women who use Paragard and other forms of birth control. Contraceptive continuation rate for Paragard is 86%, compared to 84% for Implant and 54% for Pill

LNG-20-IUS=Ievonorgestrel 20 mcg/day intrauterine system.

Bleeding Profile

Paragard users may experience heavier and longer periods with spotting in between. Sometimes the bleeding is heavier than usual at first, but subsides.

Paragard will not interfere with her natural menstrual cycle or stop ovulation.

  • Many women may wish to keep a menstrual cycle for a variety of personal or cultural reasons4

Patients should be advised to call you if spotting persists or their menstrual flow continues to be heavy or long. If a woman misses her period, she must promptly be evaluated for pregnancy.

Important Safety Information

  • Paragard must not be used by women who had a post-pregnancy or post-abortion uterine infection in the past 3 months; have cancer of the uterus or cervix; acute pelvic inflammatory disease (PID); an infection of the cervix; an allergy to any component (including copper); or Wilson’s disease. Continue reading

Indication

Paragard is a copper-containing IUS (intrauterine system) indicated for the prevention of pregnancy for up to 10 years.

Important Safety Information

  • Paragard must not be used by women who had a post-pregnancy or post-abortion uterine infection in the past 3 months; have cancer of the uterus or cervix; acute pelvic inflammatory disease (PID); an infection of the cervix; an allergy to any component (including copper); or Wilson's disease.
  • If a woman misses her period, she must be promptly evaluated for ectopic pregnancy.
  • Possible serious complications that have been associated with IUSs are PID, embedment, perforation of the uterus, and expulsion.
  • Paragard must not be used by pregnant women as this can be life threatening and may result in loss of pregnancy or infertility.
  • Menstrual cycles may become heavier and longer with intermenstrual spotting. Bleeding may be heavier than usual at first.
  • Paragard does not protect against HIV or STIs.

Please see accompanying Full Prescribing Information.

References:
1. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine copper T-380A contraceptive device. lnt J Womens Health. 2010;2:211-220.

2. Diedrich JT, Desai S, Zhao Q, et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212(1): 50.e1-50.e8.

3. Rosenstock JR, Peipert JF, Madden T, et al. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012;120(6):1298-1305.

4. Data on file. CooperSurgical, Inc.

*LARC=Long-Acting Reversible Contraceptive.

†From the Contraceptive CHOICE Project (n=7,472). The (n=2,956) is a subset of the total (n=7,472). A prospective cohort study to determine the continuation rates and satisfaction levels with many reversible methods of contraception. To be included in this analysis, study participants had to initiate their chosen contraceptive within 3 months of CHOICE enrollment and reach the time point for a 12-month follow-up telephone survey. Follow-up telephone interviews were conducted at 3, 6, and 12 months. A “continuer” was a participant who reported using her baseline contraceptive without stopping temporarily for ≥1 month.

‡Chart does not compare the safety or efficacy of these methods.